Ifosfamide
- Atc Codes:L01AA06
- CAS Codes:3778-73-2
- PHARMGKB ID:3778-73-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Holoxan; Belgium: Holoxan; Bulgaria: Holoxan; Cyprus: Holoxan; Czech Republic: Holoxan; Denmark: Holoxan, Ifosfamid; Estonia: Holoxan; Finland: Holoxan; France: Holoxan; Germany: Holoxan, IFO-Cell; Greece: Holoxan; Ireland: Mitoxana; Italy: Holoxan; Latvia: Holoxan; Lithuania: Holoxan; Luxembourg: Holoxan; Malta: Ifosfamide; Netherlands: Holoxan; Poland: Holoxan, Macdafen; Portugal: Holoxan; Romania: Holoxan; Slovakia: Holoxan; Slovenia: Holoxan; Spain: Tronoxal; Sweden: Holoxan; UK: Mitoxana.
North America
Canada: Ifex, Ifosfamide; USA: Ifosfamide.
Latin America
Argentina: Cuantil, Ifocris, Ifosfamida, Ifosmixan, IFX; Brazil: Holoxane, Ifosfamida; Mexico: Alquimid, Fosfidex, Ifadex, Ifolem, Ifomida, Ifosfamida.
Asia
Japan: Ifomide.
Drug combinations
Ifosfamide and Mesna
Chemistry
Ifosfamide: C~7~H~15~Cl~2~N~2~O~2~P. Mw: 261.09. (1) 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; (2) 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide. CAS-3778-73-2 (1978).
Pharmacologic Category
Antineoplastic Agents; Alkylating Agents; Nitrogen Mustard. (ATC-Code: L01AA06).
Mechanism of action
Causes cross-linking of strands of DNA by binding with nucleic acids and other intracellular structures. Inhibits protein synthesis and DNA synthesis.
Therapeutic use
Treatment of testicular cancer.
Pregnancy and lactiation implications
Increased resorptions and embryotoxic effects observed in animal studies. Enters breast milk.
Unlabeled use
Treatment of bladder, breast, cervical, ovarian, pancreatic and lung cancers. Hodgkin’s and non-Hodgkin lymphoma. Acute lymphocytic leukemia. Ewing’s sarcoma, osteosarcoma, and soft tissue sarcomas.
Contraindications
Hypersensitivity to ifosfamide or any component of the formulation. Severely depressed bone marrow function.
Warnings and precautions
Hazardous agent. Severe bone marrow suppression might occur (use with caution in compromised bone marrow reserve; use contraindicated in severely depressed bone marrow function). May cause CNS toxicity (coma, confusion, encephalopathy). Urotoxic side-effects, primarily hemorrhagic cystitis, might occur. Might interfere with wound healing. Use with caution in renal impairment.